Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
MGNX · NASDAQ · Pharmaceutical Preparations
$1.96−0.02 (−1.01%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Macrogenics (MGNX) · oqro.io/stocks/MGNX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Everything reported about this company, newest first. Each line shows the dates that matter for its source.
Planned sale · Planned for Oct 22, 2026 · Notice filed Oct 22, 2026
Director filed to sell about $79K of MGNX stockSourceInsider trade · Traded Aug 19, 2026 · Filed Aug 20, 2026
Officer sold ~$129K of MGNX shares in the open marketSourceFund moves · Holdings as of Dec 31, 2025 (Q4 2025) · Filed Feb 17, 2026
Bellevue Group AG no longer reported MGNX for Q4 2025SourceInsider trade · Traded Aug 19, 2025 · Filed Aug 21, 2025
Director purchased ~$77K of MGNX shares in the open marketSourceInsider trade · Traded Aug 20, 2025 · Filed Aug 21, 2025
Director purchased ~$74K of MGNX shares in the open marketSourceInsider trade · Traded Feb 15, 2025 · Filed Feb 19, 2025
Officer sold ~$1.1K of MGNX shares in the open marketSourceFund moves · Holdings as of Dec 31, 2024 (Q4 2024) · Filed Feb 18, 2025
Frazier Life Sciences Management, L.P. disclosed an increased position in MGNX for Q4 2024Source